Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 3: Long-term Objective B  

Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.3LB. Identify genetic risk factors in at least 50% of people with ASD by 2014. IACC Recommended Budget: $33,900,000 over 6 years.

Download 2010 Question 3: Long-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
The frequency of polymorphisms in maternal- and paternal-effect genes in autism spectrum Levine, Arnold Princeton University
Hypocholesterolemic autism spectrum disorder Porter, Forbes National Institutes of Health
Genetic epidemiology of complex traits Bailey-Wilson, Joan National Institutes of Health
The transcription factor PLZF: A possible genetic link between immune dysfunction and autism Sant'Angelo, Derek Memorial Sloan-Kettering Cancer Center
The role of the neurexin 1 gene in susceptibility to autism Gusella, James Massachusetts General Hospital/Harvard Medical School
Investigation of genes involved in synaptic plasticity in Iranian families with ASD Santangelo, Susan Massachusetts General Hospital
Genes disrupted by balanced genomic rearrangements in autism spectrum disorders Gusella, James Massachusetts General Hospital
Comprehensive follow-up of novel autism genetic discoveries Daly, Mark Massachusetts General Hospital
A recurrent genetic cause of autism Gusella, James Massachusetts General Hospital
Role of TSC/mTOR signaling pathway in autism and autism spectrum disorders Ramesh, Vijaya Massachusetts General Hospital
Integrative genetic analysis of autistic brains Arking, Dan Johns Hopkins University School of Medicine
The role of contactin-associated protein-like 2 (CNTNAP2) and other novel genes in autism Chakravarti, Aravinda Johns Hopkins University School of Medicine
Understanding glutamate signaling defects in autism spectrum disorders Wang, Tao Johns Hopkins University
The role of retrotransposons in autism spectrum disorders Kazazian, Haig Johns Hopkins University
Illumina, Inc. No PI listed Illumina, Inc.
Population genetics to improve homozygosity mapping and mapping in admixed groups Williams, Amy Harvard Medical School
Dense mapping of candidate regions linked to autistic disorder Gregersen, Peter Feinstein Institute For Medical Research
Comprehensive genetic variation detection to assess the role of the X chromosome in autism Warren, Stephen Emory University
Simons Simplex Collection Site Lese Martin, Christa Emory University
Whole-genome sequencing for rare highly penetrant gene variants in schizophrenia Goldstein, David Duke University
Simons Simplex Collection Site Peterson, Bradley Columbia University
Genetic basis of autism Wigler, Michael Cold Spring Harbor Laboratory
Genome-wide association study of autism characterized by developmental regression Molloy, Cynthia Cincinnati Children's Hospital Medical Center
Potential role of non-coding RNAs in autism Talebizadeh, Zohreh Children's Mercy Hospitals And Clinics
Uncovering genetic mechanisms of ASD Kunkel, Louis Children's Hospital Boston

Objective Multiyear Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Identify genetic risk factors in at least 50% of people with ASD by 2014.

IACC Recommended Budget: $33,900,000 over 6 years
83 projects

79 projects

60 projects

59 projects

74 projects

3.L.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: Further work is needed to identify genetic risk factors in at least 50% of people. Currently, whole exome analysis predicts that a genetic risk factor can be identified for 20% of people; inclusion of CNV data might push this toward 30%.

Remaining Gaps, Needs, and Opportunities: The initial budget recommendation for this objective was made based on the assumption that GWAS studies would provide risk factor identification, but sequencing has proven more fruitful. Since this technique is more expensive, a higher budget will be required to meet the goal of 50%.